POS1238 EVALUATING OUTCOMES FOR PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS TREATED WITH OBINUTUZUMAB, A HUMANISED ANTI-CD20 MONOCLONAL ANTIBODY, FOLLOWING SECONDARY NON-DEPLETION OF B CELLS AND NON-RESPONSE WITH RITUXIMABM. Leandro, Michael R. Ehrenstein, Corinne Fisher et al.|Annals of the Rheumatic Diseases|2025Cited by 0